AbbVie's bread winner is Humira - this drug accounts for the majority of their revenue. However, they did forecast that by 2020, revenue from Humira will be $21B - which is about 75% of their 2017 revenue of $28.22B. Since AbbVie depends so heavily on their flagship, their stock is fairly volatile, giving this play more of a risk. Consider well-hedged positions...
We have been long ABBV for a while! The stock is gapping up today after the company announced a cash tender offer for up to $7.5B of its common stock at prices between $99 and 114 per share.
Dear Viewers, Welcome to my First Forex Technical Analysis. Let´s get straight to the point, NYSE:ABBV is going through a very nice shaped Head and Shoulder Pattern. For now, as we only have the left shoulder, we can´t predict how high the head will be, or how low the correction after this H&S pattern will go, because the size of the Head and Shoulders...
Huge breakout for ABBV closing the day above the double top formed from 2014/2015 highs between 70.70 and 71.60, both offering little resistance. RSI pushing into the high 80s shows good strong move up in my opinion, I won't be using RSI for short/sell/TP signal, rather buy more when it dips to over-sold territory on consolidation in the next few weeks... if that...
Main Signals: 1-rising wedge with bottom line's breakout 2-RSI divergence Sell current low breakout 66.34 Stop loss 68.13 (+1 tic wedge high) Target 55.50 (Elliott's waves+stron price levels)